时间：2019年10月11日 (周五) 上午10:00-11:00
　　Time：October 11, 2019, 10:00-11:00 AM
　　地点：西湖大学云栖校区5号楼1楼报告厅
　　Venue:Lecture Hall, 1st Floor, Build 5, Yunqi Campus
　　主持人：生命科学学院卢培龙博士
　　Host：Dr. Peilong Lu, School of Life Sciences, Westlake University
　　主讲嘉宾/Speaker:

　　Dr. Ting He
　　CEO of ImmunoChina Pharmaceuticals
　　

讲座摘要/Abstract:
　　CD19-targeted chimeric antigen receptor-T (CAR-T) cells with CD28 or 4-1BB co-stimulatory domains (28z CAR-T and BBz CAR-T) have been approved by FDA to treat relapsed or refractory (r/r) B cell hematological malignancies. However, comparison of their clinical outcomes has never been reported. We established self-innovative platform technology of CAR-T manufacture, and investigated the clinical performances of both CAR-T types in B-ALL and B-NHL therapy based on exploratory clinical trials. Results showed that BBz CAR-T achieved higher complete response rate than 28z CAR-T in B-ALL therapy, and similar overall response rate was observed in B-NHL therapy. Most importantly, BBz CAR-T was well tolerated, however, 28z CAR-T induced severe cytokine release syndrome and neurotoxicity in B-ALL and B-NHL therapy. Our study suggests that 4-1BB is more beneficial for the clinical performance of CAR-T cells than CD28 in CD19-targeted therapy, at least under our manufacturing process.
　　

联系人/Contact：
　　生命科学学院
　　于文越 yuwenyue@westlake.edu.cn